Substance / Medication

Quetiapine fumarate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Bipolar disorder

Autistic disorder of childhood onset

Schizophrenia

Psychotic disorder

Schizophrenic disorders

Major depressive disorder

Infantile autism

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Creatinine

LOINC 2160-0

secondary

Sodium

LOINC 2951-2

secondary

Thyrotropin

LOINC 3016-3

secondary

Research Evidence

Published studies and systematic reviews

Sort:

Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients.

Vatsalya Vatsalya, Pandey Akash, Schwandt Melanie L et al. · Clin Drug Investig · 2016

PMID: 27503091RCTFull text (PMC)

Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.

Gonçalves de Lima L, Rossi de Campos D · Drug Res (Stuttg) · 2016

PMID: 26697891RCT

Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.

Bauer Michael, Thase Michael E, Liu Sherry et al. · J Psychopharmacol · 2015

PMID: 25257148RCT

Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.

Montgomery Stuart A, Altamura A Carlo, Katila Heikki et al. · Int Clin Psychopharmacol · 2014

PMID: 24162081RCT

Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study.

McIntyre Alexander, Paisley David, Kouassi Edouard et al. · Arthritis Rheumatol · 2014

PMID: 24504819RCT

Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.

Li Qian, Su Yun Ai, Liu Yi et al. · Clin Pharmacokinet · 2014

PMID: 24385309RCT

Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate.

Clayton Anita H, Locklear Julie C, Svedsäter Henrik et al. · CNS Spectr · 2014

PMID: 24067192RCT

Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.

Sheehan David V, Svedsäter Henrik, Locklear Julie C et al. · J Affect Disord · 2013

PMID: 24135509RCT

Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.

Thase Michael E, Demyttenaere Koen, Earley Willie R et al. · Depress Anxiety · 2012

PMID: 22753280RCT

Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.

Sheehan David V, Locklear Julie, Svedsäter Henrik et al. · Int Clin Psychopharmacol · 2012

PMID: 22859063RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Psychiatry Physician

Psychiatry & Neurology — Psychiatry

NUCC 2084P0800X

Find a Provider

Health Goals

Goals connected through associated conditions

Support Mental Wellness

Quick Facts

Type: Substance / Medication
Fully Specified Name: Quetiapine fumarate (substance)
SNOMED CT: 108383008
UMLS CUI: C0724680

Clinical Data

This intervention maps to 12 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.